Latest Developments and Insights

In drug development, and especially for smaller and medium-sized biotech companies, consistency is everything. From regulatory pathways to R&D timelines to global supply chains — predictability enables progress. But there’s one growing source of disruption that biotech leaders are increasingly…

As a medicinal chemist with experience in large pharmaceutical companies, I’ve spent my career designing and optimizing drug candidates. But when I was tasked with advancing a highly potent cytotoxic peptide-drug conjugate (PDC) toward IND submission, I found myself in…

The landscape of analytical development is continually evolving. With the introduction of ICH Q14: Analytical Procedure Development, the pharmaceutical and biotech sectors now have a formalized framework to guide the creation, validation, and lifecycle management of analytical methods. To keep…

With a focus on people, process, and technology, Syner-G BioPharma Group empowers life science organizations with the knowledge and expertise needed to develop and execute their lab relocation strategies with confidence. By Jasmina Xie, Sr. Project Manager and Construction Manager,…

In order to maintain competitiveness, life science organizations are leveraging technology now more than ever to enhance decision-making, create innovative business models, and improve customer experiences. Many are considering the integration of new technology as a strategic move to streamline…

The ongoing U.S.-China trade war, now entering its seventh year, has evolved beyond tariffs into a broader strategic contest over technology, industrial policy, and national security. For the pharmaceutical sector — particularly the supply chains evolved to manufacture investigational drugs…